Cargando…

Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts

Tumor-associated tertiary lymphoid structures (TA-TLS) are associated with enhanced patient survival and responsiveness to cancer therapies, but the mechanisms underlying their development are unknown. We show here that TA-TLS development in murine melanoma is orchestrated by cancer-associated fibro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Anthony B., Peske, J. David, Woods, Amber N., Leick, Katie M., Mauldin, Ileana S., Meneveau, Max O., Young, Samuel J., Lindsay, Robin S., Melssen, Marit M., Cyranowski, Salwador, Parriott, Geoffrey, Conaway, Mark R., Fu, Yang-Xin, Slingluff, Craig L., Engelhard, Victor H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362934/
https://www.ncbi.nlm.nih.gov/pubmed/34289373
http://dx.doi.org/10.1016/j.celrep.2021.109422
Descripción
Sumario:Tumor-associated tertiary lymphoid structures (TA-TLS) are associated with enhanced patient survival and responsiveness to cancer therapies, but the mechanisms underlying their development are unknown. We show here that TA-TLS development in murine melanoma is orchestrated by cancer-associated fibroblasts (CAF) with characteristics of lymphoid tissue organizer cells that are induced by tumor necrosis factor receptor signaling. CAF organization into reticular networks is mediated by CD8 T cells, while CAF accumulation and TA-TLS expansion depend on CXCL13-mediated recruitment of B cells expressing lymphotoxin-α(1)β(2). Some of these elements are also overrepresented in human TA-TLS. Additionally, we demonstrate that immunotherapy induces more and larger TA-TLS that are more often organized with discrete T and B cell zones, and that TA-TLS presence, number, and size are correlated with reduced tumor size and overall response to checkpoint immunotherapy. This work provides a platform for manipulating TA-TLS development as a cancer immunotherapy strategy.